 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 February 1997 | Volume 126 Issue 3 | Pages 184-192
Background: Although many patients now survive the short-term complications of bone marrow transplantation for life-threatening hematologic disease, information on the health and activity of long-term survivors is sparse.
Objective: To evaluate the morbidity and mortality of patients surviving more than 5 years after allogeneic bone marrow transplantation.
Design: Retrospective, multicenter study.
Patients: 798 recipients of bone marrow transplants (477 adults, 321 children) from 43 European centers. Patients had received transplants before December 1985 and had survived at least 5 years. Patients had received allogeneic or syngeneic bone marrow for leukemia, lymphoma, inborn diseases of the hematopoietic and immune systems, and severe aplastic anemia.
Measurements: Survival, clinical performance according to Karnofsky score (in increments of 10%), and social reintegration were assessed as outcomes. Patient age and sex, primary disease and status at transplantation, histocompatibility of the donor, conditioning regimen, type of prophylaxis of graft-versus-host disease, and acute and chronic graft-versus-host disease were evaluated as variables.
Results: For the 55 5-year survivors, actuarial mortality was 8% at 10 years and 14% at 15 years. The leading causes of death were disease recurrence (21 patients), chronic graft-versus-host disease with complicating infections and lung disease (11 patients), secondary cancer (8 patients), and the acquired immunodeficiency syndrome (AIDS) (5 patients). When patients with recurrent disease were excluded, late death was associated with chronic graft-versus-host disease (P < 0.001), occurrence of secondary cancer (P < 0.001), male sex of the patient (P = 0.05), and female sex of the donor (P = 0.002). Clinical performance was normal (Karnofsky score, 100%) or minimally reduced (Karnofsky score, 90%) in 93% of patients; 89% of patients resumed full-time work or school. Reduced performance status and incomplete resumption of social activity were associated with chronic graft-versus-host disease, recurrent leukemia, AIDS, secondary cancer, organ dysfunction, and neurologic or psychological problems. Other risk factors for incomplete resumption of social activity were female sex (P = 0.002) and older age at transplantation (P = 0.001).
Conclusions: More than 5 years after bone marrow transplantation, most patients were in good health (93%) and had returned to full-time work or school (89%). Recurrence of the primary disease, secondary cancer, and chronic graft-versus-host disease and its sequelae remain problems for some patients.
Author and Article Information
For the EBMT Working Party on Late Effects and EULEP Study Group on Late Effects
ARTICLE
Health and Functional Status of Long-Term Survivors of Bone Marrow Transplantation
Grant Support: In part by European Late Effect Project Group (EULEP) and Commission of European Community contract FI3P-CT920064f (for epidemiologic studies and tables).
Requests for Reprints: Hans-Jochem Kolb, MD, PhD, Medizinische Klinik III, Knochenmarktransplantation, Klinikum Gro ß hadern, Universitat Munchen, Marchioninistrasse 15, 81377 Munchen, Germany.
Current Author Addresses: Dr. Duell: Center for Molecular Cytogenetics, Life Sciences Division, Lawrence Berkeley National Laboratory, MS 74-157, 1 Cyclotron Road, Berkeley, CA 94720.
This article has been cited by other articles:
|
|
 |
|
  A. Rovo, T. Daikeler, M. Stern, J. Halter, J. D. Studt, A. Buser, D. Heim, J. Rischewski, M. Medinger, A. Tyndall, et al. Physical and not mental health is impaired in very long-term survivors after HSCT compared with their respective donors: a paired analysis Blood, February 1, 2008; 111(3): 1740 - 1741. [Full Text] [PDF]
|
|
|
|
|
|
A. Tichelli Hematopoietic cell transplantation: a lifelong commitment Blood, November 15, 2007; 110(10): 3493 - 3494. [Full Text] [PDF]
|
|
|
|
|
|
S. Bhatia, L. Francisco, A. Carter, C.-L. Sun, K. S. Baker, J. G. Gurney, P. B. McGlave, A. Nademanee, M. O'Donnell, N. K. C. Ramsay, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study Blood, November 15, 2007; 110(10): 3784 - 3792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Shankar, A. Carter, C.-L. Sun, L. Francisco, K. S. Baker, J. G. Gurney, D. G. Weisdorf, S. J. Forman, L. L. Robison, M. Grant, et al. Health Care Utilization by Adult Long-term Survivors of Hematopoietic Cell Transplant: Report from the Bone Marrow Transplant Survivor Study Cancer Epidemiol. Biomarkers Prev., April 1, 2007; 16(4): 834 - 839. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fraser, S. Bhatia, K. Ness, A. Carter, L. Francisco, M. Arora, P. Parker, S. Forman, D. Weisdorf, J. G. Gurney, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study Blood, October 15, 2006; 108(8): 2867 - 2873. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Syrjala, S. L. Langer, J. R. Abrams, B. E. Storer, and P. J. Martin Late Effects of Hematopoietic Cell Transplantation Among 10-Year Adult Survivors Compared With Case-Matched Controls J. Clin. Oncol., September 20, 2005; 23(27): 6596 - 6606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Ness, S. Bhatia, K. S. Baker, L. Francisco, A. Carter, S. J. Forman, L. L. Robison, J. Rosenthal, and J. G. Gurney Performance Limitations and Participation Restrictions Among Childhood Cancer Survivors Treated With Hematopoietic Stem Cell Transplantation: The Bone Marrow Transplant Survivor Study Arch Pediatr Adolesc Med, August 1, 2005; 159(8): 706 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bhatia, L. L. Robison, L. Francisco, A. Carter, Y. Liu, M. Grant, K. S. Baker, H. Fung, J. G. Gurney, P. B. McGlave, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study Blood, June 1, 2005; 105(11): 4215 - 4222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tichelli and G. Socie Considerations for Adult Cancer Survivors Hematology, January 1, 2005; 2005(1): 516 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. L. Stewart, B. Storer, J. Storek, H. J. Deeg, R. Storb, J. A. Hansen, F. R. Appelbaum, P. A. Carpenter, J. E. Sanders, H.-P. Kiem, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease Blood, December 1, 2004; 104(12): 3501 - 3506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Lee, S. Joffe, H. T. Kim, G. Socie, A. L. Gilman, J. R. Wingard, M. M. Horowitz, D. Cella, and K. L. Syrjala Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation Blood, October 1, 2004; 104(7): 2194 - 2200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Syrjala, S. L. Langer, J. R. Abrams, B. Storer, J. E. Sanders, M. E. D. Flowers, and P. J. Martin Recovery and Long-term Function After Hematopoietic Cell Transplantation for Leukemia or Lymphoma JAMA, May 19, 2004; 291(19): 2335 - 2343. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Socie, N. Salooja, A. Cohen, A. Rovelli, E. Carreras, A. Locasciulli, E. Korthof, J. Weis, V. Levy, and A. Tichelli Nonmalignant late effects after allogeneic stem cell transplantation Blood, May 1, 2003; 101(9): 3373 - 3385. [Full Text] [PDF]
|
|
|
|
|
|
S. J. Lee, J. P. Klein, A. J. Barrett, O. Ringden, J. H. Antin, J.-Y. Cahn, M. H. Carabasi, R. P. Gale, S. Giralt, G. A. Hale, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse Blood, June 28, 2002; 100(2): 406 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Wingard, G. B. Vogelsang, and H. J. Deeg Stem Cell Transplantation: Supportive Care and Long-Term Complications Hematology, January 1, 2002; 2002(1): 422 - 444. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. Lee, D. Fairclough, S. K. Parsons, R. J. Soiffer, D. C. Fisher, R. L. Schlossman, J. H. Antin, and J. C. Weeks Recovery After Stem-Cell Transplantation for Hematologic Diseases J. Clin. Oncol., January 1, 2001; 19(1): 242 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Wheeler, S. M. Richards, C. C. Bailey, B. Gibson, I. M. Hann, F. G. H. Hill, and J. M. Chessells Bone marrow transplantation versus chemotherapy in the treatment of very high-risk childhood acute lymphoblastic leukemia in first remission: results from Medical Research Council UKALL X and XI Blood, October 1, 2000; 96(7): 2412 - 2418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mounier, C. Haioun, B. F. Cole, C. Gisselbrecht, C. Sebban, P. Morel, G. Marit, R. Bouabdallah, C. Ravoet, G. Salles, et al. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission Blood, June 15, 2000; 95(12): 3687 - 3692. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Socie, J. V. Stone, J. R. Wingard, D. Weisdorf, P. J. Henslee-Downey, C. Bredeson, J.-Y. Cahn, J. R. Passweg, P. A. Rowlings, H. C. Schouten, et al. Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation N. Engl. J. Med., July 1, 1999; 341(1): 14 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Thomas Does Bone Marrow Transplantation Confer a Normal Life Span? N. Engl. J. Med., July 1, 1999; 341(1): 50 - 51. [Full Text]
|
|
Article
